-- 永明金融（Sun Life Financial，股票代碼：SLF.TO）週四盤後宣布，已就一項涉及大都會人壽（MetLife）在上世紀八九十年代銷售和簽發的個人壽險保單的集體訴訟達成原則性和解。這些保單是永明金融透過收購繼承的。 該公司表示，此事不涉及永明金融銷售的任何保單或產品。 如果獲得批准，永明金融將向符合資格的保單持有人支付高達2.135億美元的和解金，預計將導致其2026年第一季報告的淨利潤增加約1.45億美元。 該訴訟涉及對保單條款的解釋，這些保單受大都會人壽的賠償保證約束。永明金融確認，如果和解獲得批准，將根據賠償保證向大都會人壽尋求全額賠償。 此外，AM Best確認了Sun Life Financial旗下核心保險子公司——加拿大永明人壽保險公司（Sun Life Assurance Company of Canada）和美國永明人壽健康保險公司（Sun Life and Health Insurance Company (U.S.)）的財務實力評級（FSR）為A+（優秀），長期發行人信用評級（Long-Term ICR）為「aa」（優秀）。 AM Best同時確認了SLF的長期發行人信用評等（Long-Term ICR）為「a」（優），長期發行人信用評等（Long-Term IR）。這些評級的展望均為穩定。 這些評級反映了Sun Life集團強勁的資產負債表實力（AM Best評估為最強）、穩健的經營業績、良好的業務狀況以及非常強大的企業風險管理能力。 Sun Life Financial的股價在美國盤後交易中持平於72.08美元。該股在多倫多證券交易所收盤上漲1.30美元，報97.87美元。
Related Articles
Research
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
$HLT
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
$UHS
Asia
Briscoe Group Fiscal Q1 Sales Tick Higher
Briscoe Group (NZE:BGP, ASX:BGP) said its sales for the fiscal first quarter ended April 26 increased over 1% year over year to NZ$180.8 million, according to Friday filings with the Australian and New Zealand bourses.Sales in the company's homeware segment rose 2% to NZ$105.7 million, and sporting goods sales edged 0.5% higher to NZ$75.1 million.The company said discretionary consumer spending has dampened due to the Middle East conflict, with a noticeable impact on the retail sector during the latter part of the quarter, while bad weather in New Zealand also had a negative impact on store traffic.
$ASX:BGP$NZE:BGP